La Trobe
- No file added yet -

Transcriptomic analysis and fusion gene identifications of midbody remnants released from colorectal cancer cells reveals they are molecularly distinct from exosomes and microparticles

Download (5.14 MB)
journal contribution
posted on 2024-07-08, 04:26 authored by Wittaya Suwakulsiri, Rong Xu, Alin RaiAlin Rai, Maoshan Chen, Adnan ShafiqAdnan Shafiq, David GreeningDavid Greening, Richard SimpsonRichard Simpson

Abstract: Previously, we reported that human primary (SW480) and metastatic (SW620) colorectal (CRC) cells release three classes of membrane-encapsulated extracellular vesicles (EVs); midbody remnants (MBRs), exosomes (Exos), and microparticles (MPs). We reported that MBRs were molecularly distinct at the protein level. To gain further biochemical insights into MBRs, Exos, and MPs and their emerging role in CRC, we performed, and report here, for the first time, a comprehensive transcriptome and long noncoding RNA sequencing analysis and fusion gene identification of these three EV classes using the next-generation RNA sequencing technique. Differential transcript expression analysis revealed that MBRs have a distinct transcriptomic profile compared to Exos and MPs with a high enrichment of mitochondrial transcripts lncRNA/pseudogene transcripts that are predicted to bind to ribonucleoprotein complexes, spliceosome, and RNA/stress granule proteins. A salient finding from this study is a high enrichment of several fusion genes in MBRs compared to Exos, MPs, and cell lysates from their parental cells such as MSH2 (gene encoded DNA mismatch repair protein MSH2). This suggests potential EV-liquid biopsy targets for cancer detection. Importantly, the expression of cancer progression-related transcripts found in EV classes derived from SW480 (EGFR) and SW620 (MET and MACCA1) cell lines reflects their parental cell types. Our study is the report of RNA and fusion gene compositions within MBRs (including Exos and MPs) that could have an impact on EV functionality in cancer progression and detection using EV-based RNA/ fusion gene candidates for cancer biomarkers.

Funding

WS., R.X., A.R., A.S., M.C., D.W.G., and R.J.S. acknowledge funding support from La Trobe University, Melbourne, Australia. W.S is supported by a La Trobe University Postgraduate Scholarship. The authors acknowledge the La Trobe University-Comprehensive Proteomics Platform for providing infrastructure.

History

Publication Date

2024-06-01

Journal

Proteomics

Volume

24

Issue

11

Article Number

2300058

Pagination

17p.

Publisher

Wiley

ISSN

1615-9853

Rights Statement

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2024 The Authors. PROTEOMICS published by Wiley-VCH GmbH.